Contextual Genomics Find It and Follow It Assays
Contextual Genomics, a Vancouver, Canada-based cancer genomics company, said that it has completed development of two new products: an improved version of its Find It hotspot panel for detection of genomic mutations in solid tumour cancers; and its Follow It hotspot panel for detection of the same genomic mutations in blood plasma.
The Find It panel now screens for 146 somatic genome alterations found in solid tumor cancers to identify optimal therapeutic treatments and recognize acquired drug resistance mutations. The assay is supported by Contextual's cloud-based genome analysis engine (CGIRP).
The Follow It panel screens for cell-free circulating tumour DNA in plasma, and is designed to be used in patients with widespread metastatic disease at diagnosis and as a time series monitoring tool to read out tumor burden and treatment resistance. Follow It will screen for all of the same somatic genome alterations as Find It and can be used to follow disease progression for patients, including those whose tumors were initially tested with Find It.
Viracor Eurofins 16S NGS Bacterial Meningitis Test
Viracor Eurofins recently launched its 16S Next-Generation Sequencing Bacterial Meningitis test. The assay amplifies the 16S gene utilizing PCR, followed by NGS to identify and report the bacterial pathogen in a patient's CSF sample. The assay was validated to include the most common bacterial pathogens associated with meningitis: Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae, Listeria monocytogenes, Streptococcus agalactiae (Group B Strep), and Escherichia coli, as well as other less common pathogens that may be clinically important in immunocompromised patient populations (HIV-positive, solid organ transplant, or hematopoietic cell transplant patients). Physicians will receive test results for difficult-to-diagnose immunocompromised patients within three business days from specimen receipt, the company said.
Lexogen TeloPrime Full-Length cDNA Amplification Kit V2
Lexogen has launched a new version of its TeloPrime Full-Length cDNA Amplification Kit. TeloPrime allows detection and correct quantification of splice variants and their "true transcription start- and end-sites, in both short and long mRNA molecules," the firm said. According to Lexogen, the upgraded kit provides higher yields and enhanced representation of longer cDNAs from as little as 1 nanogram of RNA.
For more new products and services, please visit the New Products page on our website.